# Huang Zehua

> Huang Zehua is a seed investor at Kaitai Capital backing Medical and Health Care. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Kaitai Capital](https://shizune.co/investors/profile/kaitai-capital)
- Total investments: 4
- Last investment: Sep 2023
- Lead investor: 75%
- Last updated: Aug 2026

Huang Zehua is a Partner at Cathay Capital.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 50% |
| Health Care | 2 | 50% |
| Biotechnology | 2 | 50% |
| Pharmaceutical | 2 | 50% |
| Biopharma | 1 | 25% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 50% |
| Series A | 1 | 25% |
| Series B | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 2 | 50% |
| United States | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nafi Pharmaceuticals | Nafi Pharmaceuticals develops novel medications for central nervous system illnesses. |  | Series A | Sep 21, 2023 |  |
| Mingsight Pharmaceuticals | Mingsight, an ophthalmic medical drug developer, has initiated a clinical trial of the original innovative drug MS-553 in patients with diabetic retinopathy. This study is the world's first clinical trial of MS-553 in this indication. In the field of CLL treatment, MS-533 can be used alone or in combination with ibrutinib, BCL-2, etc.,initially showing outstanding clinical value and market potential in the treatment of patients with C481S and PLCG2 mutations; in the field of DME treatment, MS-533 can be taken orally to achieve enrichment in the retina of the fundus, avoiding the need for vitreous injection of drugs such as ranibizumab, and clinical data such as BCVA/CRT of patients also initially show the efficacy of the product. | $20M | Series B | Nov 09, 2021 |  |
| Nafi Pharmaceuticals | Nafi Pharmaceuticals develops novel medications for central nervous system illnesses. |  | Seed | Oct 21, 2021 |  |
| Aoquan | Aoquan is a biopharmaceutical company that provides research and development, production, and industrialization of innovative drugs. |  | Seed |  |  |

4 of 4 investments shown.

## Co-investors
- [Yael Capital Management Limited](https://shizune.co/investors/profile/yael-capital-management-limited) — VC Fund, 1 deal together

## About Kaitai Capital

VC Fund · Hangzhou, China

KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc.

5 contacts available at Kaitai Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Huang Zehua | Partner | https://shizune.co/investors/profile/huang-zehua |
| Jin Qi | Managing Partner | https://shizune.co/investors/profile/jin-qi-ef05 |
| Li Xianxian | Managing Partner | https://shizune.co/investors/profile/li-xianxian |
| Nannan Chang | Senior Investment Manager | https://shizune.co/investors/profile/nannan-chang |
| Xian Li | Partner | https://shizune.co/investors/profile/xian-li-67ed |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Huang Zehua invest in?

Huang Zehua invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Huang Zehua last invest?

The most recent investment recorded for Huang Zehua closed in Sep 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co